Displaying drugs 351 - 375 of 8180 in total
Pralsetinib
Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … RET RTK inhibitors for the treatment of RET-driven cancers. ... , [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of ... [A202049, A202055, L15986]
Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is …
Lovastatin
Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of Aspergillus terreus. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid...
Approved
Investigational
Matched Description: … studies to significantly reduce the risk of development of CVD and all-cause mortality. ... and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes ... [A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark …
Vinorelbine
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
It is a third-generation vinca alkaloid. The introduction...
Approved
Investigational
Matched Description: … Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies ... genetics on the clearance of this drug [L2002]. ... It was initially approved in the USA in 1990's for the treatment of NSCLC [L2010]. …
Nilutamide
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Matched Description: … Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate ... the growth of normal and malignant prostatic tissue. ... Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. …
Methimazole
Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949 and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339]...
Approved
Matched Description: … Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones. ... first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of ... the pro-drug [carbimazole], which is an antithyroid medication used in the United Kingdom and parts of …
Budesonide
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532]
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product...
Approved
Matched Description: … of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. ... Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions …
Ertugliflozin
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Approved
Investigational
Tepotinib
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell...
Approved
Investigational
Matched Description: … Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid ... [A228058] It was originally developed in partnership between EMD Serono and the University of Texas M.D ... [A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a …
Tolcapone
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Approved
Withdrawn
Matched Description: … Tolcapone is associated with a risk of hepatotoxicity. ... It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. …
Loracarbef
Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.
Approved
Investigational
Withdrawn
Ciclopirox
Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective in treating Tinea versicolor.
Approved
Investigational
Matched Description: … , Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of …
Doripenem
Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that...
Approved
Investigational
Matched Description: … in a premature termination of the trial. ... In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin ... ), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting …
Avalglucosidase alfa
Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase (GAA) enzyme. GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. In Pompe disease, the...
Approved
Investigational
Matched Description: … patients older than six months of age with late-onset Pompe disease. ... specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of ... [A232955] Avalglucosidase alfa is a recombinant form of GAA that restores deficient enzyme levels. …
Varenicline
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full...
Approved
Investigational
Matched Description: … Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine ... Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015 ... Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, …
Atomoxetine
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention...
Approved
Matched Description: … advantage over the use of traditional medications for the management of ADHD. ... Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention ... side effects and an increase in abuse potential, which is a limiting factor associated with the use of …
Diflunisal
Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the...
Approved
Investigational
Matched Description: … Though its mechanism of action has not been clearly established, most of its actions appear to be associated ... with inhibition of prostaglandin synthesis via the arachidonic acid pathway. ... Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of …
Sincalide
Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as CCK-8. Naturally occurring cholecystokinin is a gastrointestinal peptide hormone normally essential for stimulating protein and fat digestion...
Approved
Matched Description: … Furthermore, sincalide stimulates the pancreatic secretion of bicarbonate and enzymes. ... It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as _CCK- ... Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders …
Aluminum chloride
Aluminum chloride is a chemical compound with the chemical formula AlCl3. When contaminated with iron chloride, it often displays a yellow color compared to the white pure compound. It is used in various chemical applications as a Lewis base, with anhydrous aluminium trichloride being the most commonly used Lewis acid....
Approved
Investigational
Matched Description: … In antiperspirant products, FDA approves the use of aluminum chloride as an active ingredient up to 15% …
Hepatitis B Vaccine (Recombinant)
Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada.
The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis...
Approved
Withdrawn
Matched Description: … This resulted from a significant decline in the prevalence of hepatitis B antigen, the persistence of ... The hepatitis B virus induces a severe form of viral hepatitis. ... 70% in the general population and a carrier rate of up to 20%. …
Ezogabine
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy....
Approved
Investigational
Matched Description: … FDA approved in June 10, 2011 under the name of ezogabine. ... Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. …
Certolizumab pegol
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated...
Approved
Matched Description: … [A176585] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 ... The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity …
Dacomitinib
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of ... [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ... second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of …
Glimepiride
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive...
Approved
Matched Description: … Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes ... used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. ... First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class …
Regorafenib
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Approved
Matched Description: … Regorafenib is an orally-administered inhibitor of multiple kinases. ... Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. ... It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours …
Perboric acid
Perboric acid is mainly found in its salt form of sodium perborate and it can be found as a monohydrate or tetrahydrate. It is one of the peroxy acid salts with very wide functionalities in industrial settings. Perboric acid in the form of sodium perborate is approved by Health Canada...
Approved
Matched Description: … as a disinfectant of medical instruments. ... Perboric acid is mainly found in its salt form of sodium perborate and it can be found as a monohydrate ... [A33037] It is one of the peroxy acid salts with very wide functionalities in industrial settings. …
Displaying drugs 351 - 375 of 8180 in total